Sanofi Acquires Oral Alzheimer’s Drug VG-3927 for $470M

Sanofi Acquires Alzheimer's Drug for $470M

Strategic Move in Neurodegenerative Disease Field

On May 22, global pharmaceutical leader Sanofi announced a definitive agreement to acquire Vigil Neuroscience in an all-cash transaction valued at approximately $470 million. Under the terms, Sanofi will purchase all outstanding common shares of Vigil at $8 per share.

This acquisition centers around VG-3927, Vigil’s investigational oral drug targeting Alzheimer’s disease (AD). As stated in the announcement, “On May 22, global pharmaceutical giant Sanofi announced an acquisition agreement with Vigil Neuroscience to purchase all outstanding common shares at $8 per share in cash, totaling approximately $470 million.”

VG-3927: An Oral TREM2 Agonist in Clinical Trials

VG-3927 is a once-daily oral small molecule agonist targeting the TREM2 receptor. It is currently undergoing Phase I clinical evaluation and is expected to enter Phase II trials for Alzheimer's disease in the second half of this year.

The original report noted: “The drug is set to begin Phase II clinical trials for Alzheimer’s disease in the second half of this year.” Initial Phase I results (VG3927-02.101) showed that VG-3927 significantly reduced soluble TREM2 levels in cerebrospinal fluid, with reductions of up to 50%, demonstrating a robust dose-dependent response.

Contingent Value Rights Included

The deal also includes contingent value rights (CVRs), providing Vigil shareholders with an additional $2 per share if VG-3927 achieves first commercial sale. Key stakeholders, including Atlas Ventures and CEO Ivana Magovčević-Liebisch, who collectively own approximately 16.2% of the company, have agreed to support the transaction, enhancing deal certainty.

Other Pipeline Assets Not Included

Not included in the acquisition is Vigil’s other pipeline asset, VGL101, a TREM2-targeting monoclonal antibody currently in a Phase II proof-of-concept trial for ALSP (adult-onset leukoencephalopathy with axonal spheroids and pigmented glia), under the code name Iluzanebart.

Addressing Urgent Needs in Alzheimer's Treatment

Currently approved therapies for Alzheimer’s disease are unable to halt or reverse disease progression and have strict eligibility criteria. Sanofi’s move reflects the urgency in developing safer, more effective, and more accessible treatments.

As stated in the source: “Currently approved Alzheimer’s therapies cannot halt or reverse disease progression and have stringent eligibility requirements. There is an urgent need for safer, more effective, and more convenient options for Alzheimer’s patients.”

Alzheimer’s disease is the most common cause of dementia, accounting for 60% to 80% of cases. It primarily affects people aged 65 and older. An estimated 6.2 million people in the United States currently live with AD.

Strategic Investment Set the Stage

This is not Sanofi’s first engagement with Vigil Neuroscience. In June 2024, Sanofi made a $40 million strategic investment in Vigil, which included exclusive negotiation rights for the research, development, manufacturing, and commercialization of VG-3927.

The report stated: “In June 2024, Sanofi made a $40 million strategic investment in Vigil Neuroscience, including exclusive negotiation rights for research, development, manufacturing, and commercialization of VG-3927.”

Highlights

• Sanofi to acquire Vigil Neuroscience for $470 million in cash.
• VG-3927, a once-daily oral TREM2 agonist, is the key asset of the deal.
• The drug showed up to 50% reduction in CSF soluble TREM2 in Phase I data and will enter Phase II trials in late 2025.
• Vigil shareholders are eligible for an additional $2/share upon VG-3927’s commercial launch.
• Vigil’s monoclonal antibody VGL101 is not included in the acquisition.
• The acquisition highlights Sanofi’s strategic push into neurodegenerative disease therapeutics.